Summary:
In patients with predominantly intermediate-risk differentiated thyroid cancer (DTC), recombinant human thyrotropin (rhTSH) with 3.7 GBq of radioactive iodine (RAI) was found to be noninferior in effectiveness compared to thyroid hormone withdrawal (THW) with 3.7 GBq of RAI. Additionally, rhTSH demonstrated a favorable safety profile, leading to fewer adverse events compared to THW.
| PICO | Description |
|---|---|
| Population | Patients with predominantly intermediate-risk differentiated thyroid cancer (DTC). |
| Intervention | Recombinant human thyrotropin (rhTSH) with 3.7 GBq of radioactive iodine (RAI). |
| Comparison | Thyroid hormone withdrawal (THW) with 3.7 GBq of radioactive iodine (RAI). |
| Outcome | The study concluded that rhTSH was noninferior to THW in terms of effectiveness among patients with intermediate-risk DTC. Additionally, rhTSH demonstrated a favorable safety profile and resulted in fewer adverse events compared to THW. |
Source: Hui Tan, et al. “Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial.” Read article here.
